Marksans Pharma Limited published the notice for its 34th Annual General Meeting in Business Standard (English) and Lakshadeep (Marathi) newspapers on August 6, 2026. The publication includes details regarding the record date and e-voting information for shareholders. This disclosure ensures compliance with regulatory requirements for shareholder communication ahead of the upcoming meeting.

The announcement was made pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted copies of the newspaper advertisements to both BSE Limited and the National Stock Exchange of India Limited for their records. Harshavardhan Panigrahi, Company Secretary, signed the submission digitally on August 6, 2026, at 11:52:53 +05'30'.

Key Details

The notice serves as formal communication to investors regarding the procedural aspects of the AGM, including the mechanism for electronic voting. Shareholders are advised to refer to the published notices in the respective newspapers for specific dates related to the record date and the e-voting window. The company’s registered office is located at 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053.

Marksans Pharma submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the Bombay Stock Exchange and National Stock Exchange on August 4, 2026. The filing, made pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides a comprehensive overview of the company’s environmental, social, and governance (ESG) performance on a standalone basis. The report underscores the company’s global operational footprint, noting that exports constitute 100% of its total turnover, while detailing key financial metrics including a turnover of ₹1,341.47 crores and a net worth of ₹1,652.31 crores.

The submission was authorized by Harshavardhan Panigrahi, Company Secretary, and covers the period from April 1, 2025, to March 31, 2026. Marksans Pharma operates through two plants and two offices nationally, alongside an international presence involving subsidiaries in the UK, US, Europe, Canada, and Australasia. The company’s core business activities involve the research, manufacturing, and sales of generic, specialty, over-the-counter (OTC), and prescription pharmaceutical products across therapeutic areas such as pain management, oncology, and cardiovascular systems.

Governance and Material Risks

The report identifies corporate governance, business ethics, and regulatory compliance as material risks and opportunities. Marksans Pharma states that strong governance practices are critical to maintaining stakeholder confidence and avoiding regulatory sanctions. The company has implemented a Board and Committee structure to oversee these risks, supported by whistleblower mechanisms and grievance redressal policies. Mr. Mark Saldanha, Chairman & Managing Director, oversees sustainability-related issues. The company reported no complaints regarding unethical practices or human rights violations during the fiscal year.

Environmental and Operational Sustainability

Marksans Pharma detailed its environmental management practices, including waste management and energy efficiency initiatives. The company has implemented a mechanism for Zero Liquid Discharge, where Effluent Treatment Plant (ETP) treated water is reused for gardening purposes. Hazardous waste is disposed of through authorized vendors compliant with the Environment Protection Act 1986. The report highlights an initiative to separate Sewage Treatment Plants (STP) from ETPs to reduce chemical consumption, power usage, and hazardous sludge generation.

The company adheres to current Good Manufacturing Practice (cGMP) standards and norms set by international health authorities such as the US FDA, UK MHRA, and Australian TGA. Air emissions are monitored by M/s. Sadekar Enviro Engineering Pvt. Ltd., an external agency. The report notes a considerable reduction in NOx and Particulate Matter air emissions, as well as Scope 1 greenhouse gas emissions, compared to previous periods.

Employee Welfare and Social Impact

As of March 31, 2026, Marksans Pharma employed 1,685 permanent employees and workers, including 160 women. The Board of Directors comprises eight members, with two women representing 25% of the board. The company reports a 100% return-to-work rate for permanent employees who took parental leave. No complaints related to child labor, forced labor, or sexual harassment were received during the year.

The company’s Corporate Social Responsibility (CSR) initiatives focus on health and education in Goa, including free health check-up camps, distribution of medicines to underprivileged communities, and support for women and child development programs. Marksans Pharma also engages with stakeholders through regular communication channels, ensuring transparency in business practices and adherence to human rights policies.